These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 22682309)

  • 1. Platelets and cytokines: How and why?
    Garraud O; Hamzeh-Cognasse H; Cognasse F
    Transfus Clin Biol; 2012 Jun; 19(3):104-8. PubMed ID: 22682309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Transfusion of platelet concentrates].
    Rieux C; Lee K; Lavaud A; Bierling P
    Ann Med Interne (Paris); 1999 Dec; 150(8):631-41. PubMed ID: 10686645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Buffy-coat-derived pooled platelet concentrates and apheresis platelet concentrates: which product type should be preferred?
    Schrezenmeier H; Seifried E
    Vox Sang; 2010 Jul; 99(1):1-15. PubMed ID: 20059760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preparation of single donor platelet with low antibody titers for all patients.
    Romphruk AV; Cheunta S; Pakoate L; Kumpeera P; Sripara P; Paupairoj C; Romphruk A
    Transfus Apher Sci; 2012 Apr; 46(2):125-8. PubMed ID: 22365668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Platelet transfusion refractoriness and effective management of platelet alloimmunization].
    Amemiya Y
    Nihon Rinsho; 1997 Sep; 55(9):2392-8. PubMed ID: 9301306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Release of immune modulation factors from platelet concentrates during storage after photochemical pathogen inactivation treatment.
    Cognasse F; Osselaer JC; Payrat JM; Chavarin P; Corash L; Garraud O
    Transfusion; 2008 May; 48(5):809-13. PubMed ID: 18298593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Platelet storage lesion: an update on the impact of various leukoreduction processes on the biological response modifiers.
    Seghatchian J
    Transfus Apher Sci; 2006 Feb; 34(1):125-30. PubMed ID: 16376152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characteristics of the THERAFLEX UV-Platelets pathogen inactivation system - an update.
    Seghatchian J; Tolksdorf F
    Transfus Apher Sci; 2012 Apr; 46(2):221-9. PubMed ID: 22365926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Platelet crossmatch testing for donor selection.
    Slichter SJ
    Prog Clin Biol Res; 1982; 88():153-64. PubMed ID: 7100207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Platelets "Toll-like receptor" engagement stimulates the release of immunomodulating molecules].
    Cognasse F; Hamzeh-Cognasse H; Garraud O
    Transfus Clin Biol; 2008 Sep; 15(4):139-47. PubMed ID: 18842435
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunomodulatory mediators in platelet transfusion reactions.
    Morrell CN
    Hematology Am Soc Hematol Educ Program; 2011; 2011():470-4. PubMed ID: 22160076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A computerized prediction model of hazardous inflammatory platelet transfusion outcomes.
    Nguyen KA; Hamzeh-Cognasse H; Sebban M; Fromont E; Chavarin P; Absi L; Pozzetto B; Cognasse F; Garraud O
    PLoS One; 2014; 9(5):e97082. PubMed ID: 24830754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Platelets cytokines and their effects on platelet transfusion].
    Cognasse F; Osselaer JC; Garraud O
    Transfus Clin Biol; 2007 May; 14(1):69-78. PubMed ID: 17499538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Platelet immunology and the immune response].
    Garraud O; Cognasse F
    Transfus Clin Biol; 2009 May; 16(2):106-17. PubMed ID: 19443253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Generation of inflammatory cytokines and chemokines from peripheral blood mononuclear cells by HLA Class II antibody-containing plasma unit that was associated with severe nonhemolytic transfusion reactions.
    Sakagawa H; Miyazaki T; Fujihara M; Sato S; Yamaguchi M; Fukai K; Morioka M; Kato T; Azuma H; Ikeda H
    Transfusion; 2007 Jan; 47(1):154-61. PubMed ID: 17207244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current status of leukocyte and platelet administration in cancer therapy.
    Walker EM; Cannon A; Mitchum EN
    Ann Clin Lab Sci; 1983; 13(6):453-73. PubMed ID: 6197928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Consequences of transfusion of platelet antibody: a case report and literature review.
    Pavenski K; Webert KE; Goldman M
    Transfusion; 2008 Sep; 48(9):1981-9. PubMed ID: 18564398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ABO-mismatched platelet transfusions: strategies to mitigate patient exposure to naturally occurring hemolytic antibodies.
    Josephson CD; Castillejo MI; Grima K; Hillyer CD
    Transfus Apher Sci; 2010 Feb; 42(1):83-8. PubMed ID: 20034854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Platelet transfusion refractoriness responding preferentially to single donor aphaeresis platelets compatible for both ABO and HLA.
    McVey M; Cserti-Gazdewich CM
    Transfus Med; 2010 Oct; 20(5):346-53. PubMed ID: 20492602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glycans and glycosylation of platelets: current concepts and implications for transfusion.
    Sørensen AL; Hoffmeister KM; Wandall HH
    Curr Opin Hematol; 2008 Nov; 15(6):606-11. PubMed ID: 18832932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.